These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16628682)

  • 21. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.
    Marzano A; Lampertico P; Mazzaferro V; Carenzi S; Vigano M; Romito R; Pulvirenti A; Franchello A; Colombo M; Salizzoni M; Rizzetto M
    Liver Transpl; 2005 May; 11(5):532-8. PubMed ID: 15838891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
    Zeng T; Xu H; Liu JY; Lei Y; Zhong S; Zhou Z
    J Clin Pharmacol; 2014 Sep; 54(9):959-67. PubMed ID: 24964070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation.
    Cholongitas E; Vasiliadis T; Antoniadis N; Goulis I; Papanikolaou V; Akriviadis E
    Transpl Infect Dis; 2012 Oct; 14(5):479-87. PubMed ID: 22624695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.
    Neff GW; O'brien CB; Nery J; Shire N; Montalbano M; Ruiz P; Nery C; Safdar K; De Medina M; Tzakis AG; Schiff ER; Madariaga J
    Liver Transpl; 2004 Nov; 10(11):1372-8. PubMed ID: 15497163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving strategies to prevent HBV recurrence.
    Roche B; Samuel D
    Liver Transpl; 2004 Oct; 10(10 Suppl 2):S74-85. PubMed ID: 15382222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant.
    Wai CT; Prabhakaran K; Wee A; Lee YM; Dan YY; Sutedja DS; Mak K; Isaac J; Lee KH; Lee HL; Da Costa M; Lim SG
    Transplant Proc; 2004 Oct; 36(8):2313-4. PubMed ID: 15561234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    J Med Virol; 2010 Nov; 82(11):1835-42. PubMed ID: 20872709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis.
    Katz LH; Paul M; Guy DG; Tur-Kaspa R
    Transpl Infect Dis; 2010 Aug; 12(4):292-308. PubMed ID: 20002355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
    Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO
    Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.
    Ikeda F; Baba N; Takaguchi K; Kubota J; Miyoshi K; Fujioka S; Moritou Y; Takeuchi Y; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K
    J Med Virol; 2012 Oct; 84(10):1562-70. PubMed ID: 22930504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
    Zhang C; Ke W; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Drug Des Devel Ther; 2016; 10():897-910. PubMed ID: 27041994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis.
    Wadhawan M; Gupta S; Goyal N; Taneja S; Kumar A
    Liver Transpl; 2013 Sep; 19(9):1030-5. PubMed ID: 23788470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
    Lai HW; Chang CC; Chen TH; Tsai MC; Chen TY; Lin CC
    J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.